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(HAM-D). Blood samples were taken at 8:00 to 9:00 am (almost 12 
hours after the drug administration) at 4th week for measurement 
steady-state drug concentrations and genotyping. Genotyping for the 
ABCB1 gene 3435C> T (exon 26) polymorphism was performed by 
PCR/RFLP assays. Serum levels of citalopram were determined by 
high-performance liquid chromatography.
Results: We found statistically significant differences between the 
frequency of C allele for 3435C/T of patients and controls (p= 0.020) 
(Table). The efficacy of citalopram was examined for genotypes in 
2 ways comparisons as responder/nonresponder groups according 
to HAM-D scores at 6th week and also HAM-D scores at 1st, 2nd, 
and 4th weeks. There was no significant difference for 3435C/T 
between the responders and nonresponders (P = 1.000). According 
to 3435C/T genotype HAM-D scores were not statistically significant 
(F = 1.280, P = 0.279).
Table.  Genotype and allele frequencies of ABCB1 3435C/T 
polymorphism in MDD and control groups.
Group Genotype distribution, n (%) Allele frequency, n (%)
C/C C/T T/T C T
MDD (n = 56) 19 (35%) 22 (41%) 13 (24%) 60 (56%) 48 (44%)
Control (n = 70) 8 (11%) 41 (59%) 21 (30%) 57 (41%) 83 (59%)
χ 2= 10.199, df= 2, 
p= 0.006*
χ 2= 5.389, df= 1, 
p= 0.020*
Conclusion: Our results suggested that C3435T polymorphism in 
the ABCB1 gene may be an indicator of the susceptibility to major 
depression but not likely treatment response to citalopram in Turkish 
population.
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Introduction: CYP2D6 differences have already been demonstrated 
within Latin-American populations by the Iberoamerican Network 
of Pharmacogenetic CEIBA Consortium. However, until now, no 
other investigations have been developed within Costa Rica’s popu-
lation, which is of interest becuase this population has a trihybrid 
component ancestry. The present study was aimed to determine the 
frequency of CYP2D6 predicted phenotype within 3 Costa Rican 
groups with different ethnic backgrounds and to describe CYP2D6 
genotypes and allele frequencies compared with other Latin-
American populations.
Patients (or Materials) and Methods: Three hundred eighty-five 
individuals were included in the study (139 Mestizo/CRM, 197 
Amerindians/AM, and 49 Afro-Caribbeans/AC). XL-PCR and real-
time PCR were performed to determine CYP2D6 genotypes. The 
CYP2D6 variant alleles *2, *3, *4, *5, *6, *10, *17, *29, *35 and 
*41 were determined.
Results: The highest frequencies of UMs (10.1%) and PMs 
(10.2%) were found in the CRM and AM population, respec-
tively. Multiplication of active genes (5.4%) were responsible for 
the high frequency of UMs in CRM population, and the pres-
ence of CYP2D6*4 (22.6%) for PMs in AM group. As expected, 
CYP2D6*17 and *29 were higher in AC group, 18.4 and 11.2% 
respectively. However, *10 was lower in the AM population (0.3%).
Conclusion: CYP2D6 predicted phenotypes vary for UMs from 10.1 
to 3.6% and PMs from 10.2 to 1.4%, among 3 Costa Rican groups 
with different ethnic background. In addition, CYP2D6 genotype 
and allele frequencies of the Costa Rican population studied differ 
in comparison to other Latin-American populations.
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Introduction: Losartan has been suggested as a selective probe for 
CYP2C9 metabolic activity. Recently, a single nucleotide polymor-
phism (SNP) IVS8-109A> T linked to SNPs in the 5’-UTR, exon 1 
and intron 1 of the CYP2C9 gene1 has been described in association 
with a higher CYP2C9 losartan metabolic ratio (MR) in healthy 
Swedes.2 The aim of this study was to examine whether there is a 
relationship between the CYP2C9 polymorphism IVS8-109A> T and 
the losartan/E3174 MR, in a previously studied healthy population 
of Ecuadorians.3
Patients (or Materials) and Methods: The CYP2C9 IVS8-109A> T 
polymorphism was analyzed in 161 unrelated Ecuadorian subjects 
using a specific PCR-RFLP method.2 These participants had been 
previously genotyped for CYP2C9 alleles *2, *3, *4, *5 and *6 and 
phenotyped with a single oral dose of 25 mg losartan,3 and all of 
them were CYP2C9*1/*1.
Results: The frequency of the allelic IVS8-109A> T polymorphism 
in this study was 0.23. The urinary losartan/E3174 ratio was sig-
nificantly higher (p = 0.024; Student t test) in subjects with the A/A 
(IVS8-109) genotype (mean [SD], 5.1 [6.6]; n = 95) than in subjects 
with T/T (2.3 [3.7]; n = 8). Present results show that the IVS8-109T 
allele is associated with a lower CYP2C9 MR in this healthy popu-
lation of Ecuadorian subjects, which is in disagreement with previ-
ous findings in healthy Swedes that reported the IVS8-109T allele in 
association with a higher CYP2C9 MR.2
Conclusion: This study shows that the SNP IVS8-109T allele is asso-
ciated with a lower CYP2C9 MR, but further investigations need to 
be carried out to establish a molecular explanation for ultra-rapid 
CYP2C9- catalyzed metabolism.
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Introduction: Interethnic variability of drug metabolism has been 
demonstrated across Iberoamerican populations by the CEIBA 
Consortium. Drug-metabolizing enzymes genotype just predicts 
actual drug metabolic activity (phenotype) in the cases of poor 
metabolizers. For example, only 30% of ultrarapid metabolizers 
can be predicted from genotyping (Llerena et al., 2012). Moreover, 
according to EMA recommendations, development of phenotyping 
procedures for drug interactions studies and clinical research recom-
mended (EMA, 2013). Therefore, a novel cocktail approach to meas-
ure metabolic activity (metabolic ratios) of the main CYP enzymes 
in just one experiment is developed and validated to be used in the 
study of Latin-American populations.
Patients (or Materials) and Methods: Subjects were given low 
oral doses of 100-mg caffeine, 25-mg losartan, 20-mg omepra-
zole, and 30-mg dextromethorphan. Blood samples were taken 4 
hours after administering the drugs to assay the following meta-
bolic ratios in plasma: CYP1A2 (caffeine/paraxanthine), CYP2C9 
(losartan /E-3174), CYP2C19 (omeprazole/5-hydroxyomepra-
zole), CYP2D6 (dextromethorphan/ dextrorphan), and CYP3A4 
(dextromethorphan/3-methoxymorphinan). Solid phase extraction 
was utilized for analyte extraction and LC-MS/MS to quantify the 
probe drugs and metabolites.
Results: Recovery values > 80% were obtained for all analytes, and 
no carryover or relative matrix effects were observed. The analytes 
were separated and detected in 9 minutes and the method was fully 
validated, with lower limits of quantification ranging from 0.3 ng 
mL–1 for 5-hydroxyomeprazole to 3.2 ng mL–1 for paraxanthine. 
The correlation coefficient (r2) values obtained were over 0.995 for 
all analytes. According to the EMA guideline on bioanalytical method 
validation, precision and accuracy values below 15% were achieved.
Conclusion: The method was proven to be useful to measure targeted 
analytes for the evaluation of CYPs hydroxylation capacity in just 
a single experiment.
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Introduction: VKORC1, CYP2C9, and CYP4F2 responsible for 
the metabolism of warfarin. Personal and ethnic differences in the 
genetic profile reveals in determining the outcome of a drug therapy. 
Aim: to explore the frequencies of CYP2C9, VCORC1, and CYP4F2 
genotypes in Russians, compare results with ones for other nations
Patients (or Materials) and Methods: A total 91 Caucasian subjects 
were recruited into the study. Forty (48.2%) patients were male and 
age was 66.17 (10.9) years. All patients had indications to receive 
warfarin. Medical records for the patients group were reviewed for 
the relevant clinical data. 5 ml of blood was taken from each subject, 
and DNA was isolated and used for identification of the CYP2C9 
allele *1, *2, *3; G-1639A VCORC1; CYP4F2 V433M rs2108622 
C > T using real-time polymerase chain reaction-restriction fragment 
length polymorphism assay. Results were compared with other ethnic 
groups and statistically analyzed with chi-square test.
Results: We described the prevalence of CYP2C9 polymorphisms *1/*1 
(67%), *1/*2 (9,9%), *1/*3 (11%), *2/*2 (2,2%), *2/*3 (8,8%), same 
for VKORC1 GG (49,5%), GA (28,6%), AA (22,%) and CYP4F2 CC 
(57,1%), CT (34,1%), TT (7,7%). No significant deviantions from 
Hardy-Wainberg equilibrium were observed (p < 0.05). Polymorphisms’ 
frequency of CYP2C9 (P < 0.001) and VKORC1 GG, AA (P < 0.05) in 
Russian distinguish from Asian. There are no significant interethnic vari-
ations for CYP4F2 between Russian, Asian and Caucasian (P > 0.05).
Conclusion: Prevalence of carriage of CYP2C9, VKORC1 polymor-
phisms in Russian patients with high thrombotic risk is closed to 
Caucasians and distinguish from Asians but no for CYP4F2.
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Introduction: CYP3A5 is an enzyme known to be involved in metab-
olism of human hormones – progesterone and testosterone, which 
metabolism may play a role in either disease origin or treatment 
efficacy in women with stillbirth. There is a common genetic poly-
morphism leading to its increased activity (6986*> G). Our aim was 
to investigate possible role of this polymorphism in stillbirth.
Patients (or Materials) and Methods: All women admitted to gyne-
cology department of university clinics with verified diagnoses of still 
birth were considered for recruitment to the study. At the same time 
women who attended routine pregnancy registration were screened 
and recruited at the same time as the study group being matched by 
their age and concomitant diseases. All women who gave informed 
consent were recruited. Peripheral venous blood samples were drawn 
into EDTA tubes. Dna was extracted. Polymerase chain reaction in 
real time was performed to detect genetic variants of CYP3A5 *3/*1 
(6986*> G). Chi-square test was used for frequency comparisons 
using statistical software Graphpad Prizm 5.0.
Results: Fifty-three women with stillbirth were recruited to the study. 
Control group consisted of 92 matched women. Frequency of the minor 
